Evidence map›Paper›PMID 32307580›Full record

ArticleCancer immunology, immunotherapy : CII2020

Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma.

Alessandra Zecca, Valeria Barili, Diana Canetti, Valeria Regina, Andrea Olivani, Chiara Carone, Valentina Capizzuto, Barbara Zerbato, Tommaso Trenti, Raffaele Dalla Valle and 3 more

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Immunotherapy for hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Immunotherapies for hepatocellular carcinoma.Nature reviews. Clinical oncology · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Role of miRZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alessandra ZeccaLaboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Valeria BariliDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy.
Diana CanettiLaboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Valeria ReginaLaboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Andrea OlivaniLaboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Chiara CaroneToxicology and Advanced Diagnostics, Ospedale S. Agostino-Estense, Modena, Italy.
Valentina CapizzutoDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy.
Barbara ZerbatoDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy.
Tommaso TrentiToxicology and Advanced Diagnostics, Ospedale S. Agostino-Estense, Modena, Italy.
Raffaele Dalla ValleDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy.
Carlo FerrariDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy.
Elisabetta CarianiToxicology and Advanced Diagnostics, Ospedale S. Agostino-Estense, Modena, Italy.
Gabriele MissaleDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126, Parma, Italy. gabriele.missale@unipr.it.ORCID http://orcid.org/0000-0001-6691-8701
University of Parma · ITOspedale di Parma · ITAzienda Unita' Sanitaria Locale Di Modena · IT

Funding

Associazione Italiana per la Ricerca sul Cancro Accelerator Award 22794Associazione Italiana per la Ricerca sul Cancro IG 15485Cancer Research UK 26813
6 · The paper itself

Abstract

Functional rescue of NK-cells in solid tumors represents a central aim for new immunotherapeutic strategies. We have conducted a genomic, phenotypic and functional analysis of circulating NK-cells from patients with HCV-related liver cirrhosis and hepatocellular carcinoma. NK-cells were sorted from patients with HCC or liver cirrhosis and from healthy donors. Comparative mRNA gene expression profiling by whole-human-genome microarrays of sorted NK-cells was followed by phenotypic and functional characterization. To further identify possible mediators of NK-cell dysfunction, an in vitro model using media conditioned with patients' and controls' plasma was set up. Metabolic and cell motility defects were identified at the genomic level. Dysregulated gene expression profile has been translated into reduced cytokine production and degranulation despite a prevalent phenotype of terminally differentiated NK-cells. NKG2D-downregulation, high SMAD2 phosphorylation and other phenotypic and molecular alterations suggested TGF-β as possible mediator of this dysfunction. Blocking TGF-β could partially restore functional defects of NK-cells from healthy donors, exposed to TGF-β rich HCC patients' plasma, suggesting that TGF-β among other molecules may represent a suitable target for immunotherapeutic intervention aimed at NK-cell functional restoration. By an unbiased approach, we have identified energy metabolism and cell motility defects of circulating NK-cells as main mechanisms responsible for functional NK-cell impairment in patients with hepatocellular carcinoma. This opens the way to test different approaches to restore NK-cell response in these patients.

Indexed as

Cell MovementEnergy MetabolismAgedCarcinoma, HepatocellularCase-Control StudiesCytokinesCytotoxicity, ImmunologicFemaleFollow-Up StudiesHepacivirusHepatitis CHumansKiller Cells, NaturalLiver CirrhosisLiver NeoplasmsMaleCytokinesTransforming Growth Factor betaCell motilityHepatocellular carcinomaImmunometabolismNK-cellsTGF-β

Identifiers

PMID32307580
PMCPMC11027621
OpenAlexW3017140882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.